InforSense Partners with U.K.’s Leading Institutions to Combat Alzheimer’s Disease
News Dec 03, 2008
InforSense Ltd. has announced that the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service (NHS) Foundation Trust (SLaM) and Institute of Psychiatry, King’s College London will use InforSense’s translational research solutions in Alzheimer’s disease studies to advance the development of early diagnostic tools and develop personalized medicine treatments within mental health research.
For the first time, informaticians, researchers and clinicians will be able to directly access their entire patient and ‘omics’ data through a common data analysis platform. The InforSense solution will eliminate errors associated with manual data processes and bottlenecks relating to data access and analysis by non specialist end users.
“Our research centers on understanding the molecular and cellular events that take place in the brain in Alzheimer’s disease and in particular we are working on blood based biomarkers to aid early diagnosis,” said Simon Lovestone, Professor of Old Age Psychiatry at King’s College London and Director of the Biomedical Research Centre for Mental Health.
“The translational solutions that InforSense provides will enable us to have an integrated data set under a common system that informaticians, researchers and clinicians can all use to access and analyze data. This will result in improved data sharing and removal of access bottlenecks, speeding up the speed and accuracy of novel biomarker identification.”
Translational research is the practice of linking clinical and research data to identify early diagnostics, also known as biomarkers, improve disease understanding and ultimately enhance patient care.
The InforSense Translational Research solution, including the InforSense platform, ClinicalSense, GenSense, and BioSense, will be used by the Biomedical Research Centre for Mental Health to integrate and analyze patient, genotyping, transcriptomics, proteomics and MRI data to support the identification of biomarkers. Researchers will also be able to access and analyze data using the VisualSense interactive web portal.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.